Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans

• Main Authors: Alyssa Marie M. Castillo (Author), Trang T. Vu (Author), Sophia G. Liva (Author), Min Chen (Author), Zhiliang Xie (Author), Justin Thomas (Author), Bryan Remaily (Author), Yizhen Guo (Author), Uma L. Subrayan (Author), Travis Costa (Author), Timothy H. Helms (Author), Donald J. Irby (Author), Kyeongmin Kim (Author), Dwight H. Owen (Author), Samuel K. Kulp (Author), Thomas A. Mace (Author), Mitch A. Phelps (Author), Christopher C. Coss (Author)
• Format: Book
• Published: Wiley, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are lacking. Recent ICI clinical pharmacology data demo...